Volume 18, Number 9—September 2012
Dispatch
Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium
Liesbet Van Heirstraeten, Samuel Coenen, Christine Lammens, Niel Hens, Herman Goossens, and Surbhi Malhotra-Kumar
Table
Characteristics of macrolide-resistant Streptococcus pyogenes used in competition experiments and relative fitness* of the erm(A)-emm77 geno-emm-type against competitor strains, Belgium, 1999–2009
| Geno-emm-type | Macrolide MIC, mg/L |
Relative fitness (SD)† |
p value, t test | |||
|---|---|---|---|---|---|---|
| Erythromycin | Clindamycin | erm(A)-emm77 | Competitor | |||
| erm(A)-emm77 | 2 | 0.125 | ND | ND | ND | |
| erm(B)-emm28 | >512 | >512 | 1.03 (0.09) | 0.98 (0.09) | 0.662 | |
| erm(B)-emm22 | >512 | >512 | 1.27 (0.15) | 0.79 (0.09) | 0.080 | |
| erm(B)-emm11 | >512 | 256 | 2.12 (0.28) | 0.48 (0.06) | 0.013 | |
| mef(A)-emm12 | 8 | 0.125 | 1.29 (0.18) | 0.78 (0.11) | 0.105 | |
| mef(A)-emm4 | 8 | <0.03 | 1.55 (0.15) | 0.65 (0.06) | 0.047 | |
| mef(A)-emm1 | 16 | 0.5 | 1.01 (0.05) | 1.00 (0.06) | 0.934 | |
*The ability of the bacteria to survive and reproduce. ND, no data.
†Average of duplicate experiments.
Page created: August 17, 2012
Page updated: August 17, 2012
Page reviewed: August 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.